Lymphatic Dysfunction Exacerbates Cutaneous Tumorigenesis and Psoriasis-Like Skin Inflammation through Accumulation of Inflammatory Cytokines

Boki, Hikari; Kimura, Takayuki; Miyagaki, Tomomitsu; Suga, Hiraku; Blauvelt, Andrew; Okochi, Hitoshi; Sugaya, Makoto; Sato, Shinichi

doi:10.1016/j.jid.2021.05.039

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, impaired lymphatic function is linked to lymphedema, a disorder characterized by extensive swelling due to improper drainage of fluid that accumulates in tissues of limbs ( 5 ). In the context of inflammatory processes, the lymphatic vascular network appears to be expanded due to lymphatic hyperplasia and abnormal lymphangiogenesis ( 6 ), as shown in both mouse models and patient samples of inflammatory diseases, such as arthritis ( 7 ), atopic dermatitis ( 8 ), psoriasis ( 9 ), and inflammatory bowel disease ( 10 ). Distorted function of LVs has been also associated with cardiometabolic diseases ( 11 ), infection diseases ( 12 ), and more recently, neurodegenerative pathologies ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory properties of the lymphatic endothelium in the tumor microenvironment

Viúdez-Pareja,

Kreft,

García-Caballero

2023

Front. Immunol.

View full text Add to dashboard Cite

The tumor microenvironment (TME) is an intricate complex and dynamic structure composed of various cell types, including tumor, stromal and immune cells. Within this complex network, lymphatic endothelial cells (LECs) play a crucial role in regulating immune responses and influencing tumor progression and metastatic dissemination to lymph node and distant organs. Interestingly, LECs possess unique immunomodulatory properties that can either promote or inhibit anti-tumor immune responses. In fact, tumor-associated lymphangiogenesis can facilitate tumor cell dissemination and metastasis supporting immunoevasion, but also, different molecular mechanisms involved in LEC-mediated anti-tumor immunity have been already described. In this context, the crosstalk between cancer cells, LECs and immune cells and how this communication can shape the immune landscape in the TME is gaining increased interest in recent years. In this review, we present a comprehensive and updated report about the immunomodulatory properties of the lymphatic endothelium within the TME, with special focus on primary tumors and tumor-draining lymph nodes. Furthermore, we outline emerging research investigating the potential therapeutic strategies targeting the lymphatic endothelium to enhance anti-tumor immune responses. Understanding the intricate mechanisms involved in LEC-mediated immune modulation in the TME opens up new possibilities for the development of innovative approaches to fight cancer.

show abstract